NCT04767906 (CaPture) is a Phase 2 clinical trial of Cabozantinib in Hepatocellular Carcinoma, sponsored by University of Leipzig.

Who is sponsoring NCT04767906?

NCT04767906 is sponsored by University of Leipzig.

What drugs are being tested in NCT04767906?

Interventions in NCT04767906: Cabozantinib.

What condition does NCT04767906 study?

NCT04767906 studies Hepatocellular Carcinoma.

Is NCT04767906 still recruiting?

NCT04767906 is currently completed. Last updated 23 January 2025.

Last reviewed 2025-01-23 · How we verify

NCT04767906: CaPture

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

Completed Phase 2 Last updated 23 January 2025

What this trial tests

Phase 2 trial testing Cabozantinib in Hepatocellular Carcinoma in 16 participants. Completed in 19 July 2024.

Timeline

14 December 2021

Primary endpoint
19 July 2024

19 July 2024

Quick facts

Lead sponsor	University of Leipzig
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	14 December 2021
Primary completion	19 July 2024
Estimated completion	19 July 2024
Sites	5 locations across Germany

Drugs / interventions tested

Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

University of Leipzig

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CaPture trial is a prospective, multi-centre, non-randomized phase II study. Its aim is to assess feasibility, safety and efficacy signals of Cabozantinib treatment in patients with HCC and prior non-response or disease progression during a PD-1 or PD-L1 inhibitor treatment. Since the potential study population is very small, the sample size has been fixed in advance to N = 40. Time on treatment (TT) will be measured as primary endpoint.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.
Chan YT, Zhang C, Wu J, Lu P, et al · · 2024 · cited 158× · PMID 39242496 · DOI 10.1186/s12943-024-02101-z
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials.
Ascari S, Chen R, De Sinno A, Stefanini B, et al · · 2026 · cited 3× · PMID 41640611 · DOI 10.3748/wjg.v32.i3.111528

Verify or expand the search:

Other trials of Cabozantinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07187869 — Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell · Phase 1 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT06900595 — Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent · Phase 2 · recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other University of Leipzig trials

Trials by the same sponsor.

NCT07155564 — Validation of Energy Expenditure Measures Study · recruiting
NCT06656832 — Peripheral Drivers of Heart Failure Progression - the Prospective PEDAL-HF Study · NA · not yet recruiting
NCT06526013 — Cholesterol Self-testing in Patients Post Acute Coronary Syndrome · NA · recruiting
NCT06420622 — INDIcators for Clarifying the bAckground of exTreme Obesity in childRen · recruiting
NCT06269263 — Feasibility of Home-based Cardiac Rehabilitation in Patients With Chronic Heart Failure (Pilot-CRHF) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04767906 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leipzig
Last refreshed: 23 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04767906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing